Public Webinar: Addressing Challenges in Payment and Access to Treatments for Early-Stage Alzheimer’s DiseaseRegister
Alzheimer’s disease (AD) impacts a broad section of society, and while there are some treatments and behavioral interventions to address the symptoms of disease, there are currently no drugs that can modify disease progression. But, new treatments for AD are on the horizon. Many drug candidates are designed to treat patients at very early stages of disease development by modifying the disease course rather than treating symptoms, meaning that there is a possibility drugs will one day be able to delay or even prevent disease. However, earlier treatments will likely enter the market with limited evidence about the impact and duration of the treatment, raising uncertainties for payers and patients.
To address the challenges associated with uncertainty and limited data, the Duke-Margolis Center for Health Policy, with support from the Global CEO Initiative for Alzheimer’s Disease (CEOi), have explored reimbursement approaches that could enhance access and understanding of new drugs, as well as areas where improved tracking and outcomes could lead to better coverage decisions. These efforts have resulted in an issue brief, “Addressing Challenges in Payment and Access to Treatments for Early-Stage Alzheimer’s Disease,” which describes potential therapies and their impact, payment models that may be suited for reimbursement of these new therapies, needed next steps to prepare for anticipated treatments and implementation of payment models.
This webinar will provide an overview of the Duke-Margolis work, and will offer an introduction to the concepts presented in the issue brief. Representatives from the payer and manufacturer communities will offer reactions to this brief, and attendees will have an opportunity to ask questions and discuss priority next steps.
Join the Webinar:
Event address for attendees:
To receive a call back, provide your phone number when you join the event, or call the number below and enter the access code.
Call-in toll number (US/Canada)
Access code: 731 104 205
731 104 205
Date and time:
Thursday, February 13, 2020 11:00 am
Eastern Standard Time (New York, GMT-05:00)